NVIV News 1.5800 Design Source Inc (NVIV)

New Post Public Reply Private Reply Replies (0) Message Board

Apr 17, 2014 at 7:30 AM

Design Source Inc (NVIV) 1.5800 $NVIV

OTC Daily Alert Stock Watch InVivo Therapeutics Holdings Corp (OTCQB: NVIV)
WorldStockWire - Mon Mar 24, 3:46AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com

InVivo Therapeutics Reports 2013 Financial Results and Business Update
Business Wire - Mon Mar 17, 3:30PM CDT
InVivo Therapeutics Holdings Corp. (NVIV), a life sciences company focused on the development and commercialization of novel drug delivery technologies as well as biopolymer devices for the treatment of spinal cord injuries and other nervous system conditions, today reported financial results for the year ended December 31, 2013.

InVivo Therapeutics Names Tamara L. Joseph as Its General Counsel and Chief Compliance Officer
Business Wire - Mon Mar 17, 7:01AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Tamara L. Joseph as Senior Vice President, General Counsel and Chief Compliance Officer, effective March 24, 2014. Ms. Joseph comes to InVivo with extensive leadership experience in the biotechnology and pharmaceutical industries as a result of holding senior positions in the US and Europe over the past 16 years.

InVivo Therapeutics Names Thomas R. Ulich, MD as Its New Chief Scientific Officer
Business Wire - Mon Feb 24, 7:03AM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced appointment of Thomas R. Ulich, MD as Chief Scientific Officer, effective February 24, 2014.

OTC Daily Alert Stock Watch - InVivo Therapeutics Holdings Corp
WorldStockWire - Wed Feb 05, 4:15AM CST
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com

InVivo Therapeutics Holdings Corp sends amended protocol to FDA and six cllinical sites for approval
M2 - Mon Jan 06, 5:43AM CST
Biomaterials company InVivo Therapeutics Holdings Corp (OTC Markets:NVIV) reported on Friday the submission of the revised protocol and related study documents for a clinical study to test the safety of its investigational scaffold device for spinal cord repair to the US Food and Drug Administration.

InVivo Sends Amended Protocol to FDA and Six Clinical Sites
Business Wire - Fri Jan 03, 2:18PM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced that it has sent to the United States Food and Drug Administration the revised protocol and related study documents for a clinical study to test the safety of its investigational scaffold device for spinal cord repair. The revised protocol includes all changes that were conditions of approval by the FDA. On Monday, it will send the revised protocol and related study documents to six sites in the United States so that they can now begin their Institutional Review Board submissions and finalize clinical study contracts with InVivo.

Novel Health Initiative for Walgreen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 02, 5:20PM CST
Walgreen undertakes a novel initiative to help in the implementation of the Affordable Care Act.

InVivo Announces Regulatory and Clinical Promotions
Business Wire - Fri Dec 27, 8:00AM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced the promotion of Lisa Crockett to Vice President, Regulatory and Kristin Neff to Vice President, Clinical Operations. These promotions are effective January 1, 2014.

InVivo Therapeutics to Move Forward with Its First Clinical Trial After Receiving FDA Conditional Approval
Business Wire - Thu Dec 26, 1:00PM CST
InVivo Therapeutics Holdings Corp. (NVIV) announced today that it has received conditional approval from the Food and Drug Administration for proposed changes to the protocol and supporting documents for the safety trial of its first investigational product, a degradable polymer scaffold for spinal cord injury. InVivo submitted these proposed changes to the FDA on November 21, 2013 and will follow the FDA's approval conditions in their entirety in a submission to the FDA next week.

InVivo Therapeutics Holdings Corp elects Mark Perrin as CEO
M2 - Tue Dec 24, 7:14AM CST
Biomaterials company InVivo Therapeutics Holdings Corp (Other OTC:NVIV) reported on Monday the election of Mark D Perrin as its chief executive officer.

InVivo Names Mark Perrin as Its New Chief Executive Officer
Business Wire - Mon Dec 23, 3:30PM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Mark D. Perrin as Chief Executive Officer, effective January 6, 2014. Upon his appointment, Mr. Perrin will also become a member of the Board of Directors.

OTC Daily Alert Stock Watch - InVivo Therapeutics Holdings Corp. (OTCQB: NVIV)
WorldStockWire - Wed Dec 18, 4:45AM CST
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com

InVivo Therapeutics Appoints Steven McAllister as Interim CFO
Business Wire - Mon Dec 16, 7:00AM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Steven McAllister as Interim Chief Financial Officer, effective December 31, 2013. He replaces Gregory Perry, who, as previously announced, will leave December 30, 2013 to join another local biotechnology company as its Chief Financial and Business Officer.

InVivo Therapeutics Announces Promotions in Technical Operations
Business Wire - Mon Dec 09, 7:00AM CST
InVivo Therapeutics Holdings Corp. (NVIV), a pioneering biomaterials company with unique technologies for drug delivery with a focus on treatment of spinal cord injuries, today announced that William D'Agostino has been promoted to Vice President, Manufacturing & Engineering and Robert Ham has been promoted to Senior Director, Quality. These promotions are effective January 1, 2014.

InVivo Therapeutics names Christopher McNulty as VP, Business Development
M2 - Tue Nov 19, 4:05AM CST
InVivo Therapeutics Holdings Corp (OTC:NVIV), a biomaterials company with unique technologies for drug delivery with a focus on treatment of spinal cord injuries, announced on Monday the appointment of Christopher McNulty as vice president, Business Development.

InVivo Therapeutics Appoints Christopher McNulty as Vice President, Business Development
Business Wire - Mon Nov 18, 7:00AM CST
InVivo Therapeutics Holdings Corp. (NVIV), a pioneering biomaterials company with unique technologies for drug delivery with a focus on treatment of spinal cord injuries, today announced that Christopher McNulty has been appointed as Vice President, Business Development.

InVivo Therapeutics Lead Program on Track
Business Wire - Fri Nov 15, 10:00AM CST
InVivo Therapeutics Holdings Corp. (NVIV), a pioneering biomaterials company with unique technologies for drug delivery with a focus on treatment of spinal cord injuries, today confirmed that the company expects that the clinical trial of its first investigational product, a degradable polymer scaffold designed to promote healing following acute spinal cord injury, will be ready to enroll patients in the first quarter of 2014.

News and Updates on CTIX, CERP, NVIV and TRTC
ACCESSWIRE - Tue Nov 12, 12:31AM CST
News and updates on Cellceutix Corporation (OTC:CTIX), Cereplast Inc. (OTC:CERP), InVivo Therapeutics Holdings Corp. (OTC:NVIV) and Terra Tech Corp. (OTC:TRTC).

InVivo Therapeutics Reports Third Quarter 2013 Financial Results
Business Wire - Thu Nov 07, 3:14PM CST
InVivo Therapeutics Holdings Corp. (NVIV), a life sciences company focused on the development and commercialization of novel drug delivery technologies as well as biopolymer devices for the treatment of spinal cord injuries and other nervous system conditions, today reported financial results for the three and nine months ended September 30, 2013.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

NYSE Reflects on 9/11: Honoring Lives and Legacy

A Somber Day at NYSE: Reflecting on 9/11 September 11th grips the heart of NYSE every year, but this year's 25th-anniversary powerfully reverberates through its hallowed halls. The hustle of the trading floor halts for a moment at 9:20 AM ET, paying homage to those lost in the harrowing attacks. I've seen the markets flap in the wind of countless crises, but nothing's...

Melissa Rivers Brings Her Wit Back to Emmys Carpet

They say you can never go home again, but don't tell that to Melissa Rivers. Rolling the dice on nostalgia and kicking off a new chapter, she's waltzing back to the Emmys red carpet for the first time in nearly 20 years. Alright, what's in it for investors? Not much—unless you're looking to invest in nostalgia. But there's something here about legacy, reinvention, and...

Jari Spirits Set to Shake Up U.S. Market After Big Wins

Korean Spirits Jari Eyes U.S. Market Entry Some stories just have that perfect 'right time, right place' vibe, and CJ Foods' recent splash with their Korean spirits brand jari is one of them. Buckle up, because this one's about a Korean distilling sensation gearing up to hit American shores with a bang. Accolades Pave the Path Jari, the premium Korean distilled spirits...

Oil Markets Shift Focus: Pipelines Trump Drilling

Decoupling Oil Price and Production Response This oil market isn’t your usual rodeo. With Brent flirting with $100, it’s a seismic shift that’s not yielding new drills but redirecting capital to the existing infrastructure landscape. Ask yourself why we're not seeing the usual cavalry charge of new rigs. It’s simple: Pipeline mileage and producing wells have...

Intus Bio Secures $2.7M for Colorectal Cancer Test

Pioneering Efforts in Early-Onset Colorectal Cancer Detection The battlefield of colorectal cancer prevention just got a serious upgrade with Intus Bio grabbing a $2.7 million award. This ain't just pocket change—it's a shot at rewriting the script on how we approach early-onset colorectal cancer, the pesky number one cancer gnawing at the under-50 crowd. Partnering...

Modeling and Mental Health Join Forces for Wellness

A Fresh Alliance for Mental Wellness in Modeling Alright, let's shine a spotlight on a significant step in the modeling industry, a place typically less vocal about mental health. In a move that feels long overdue, Brain-Body Therapy and Mother Model Management have joined forces, marking the beginning of a collaborative effort to propel mental wellness to the forefront...

Supply Maverick Simplifies Global Shipping Processes

Paving the Way for Seamless International Shipping Supply Maverick's got a new mantra, folks: simplicity. They're slicing through the mess of international shipping and bringing some much-needed clarity for customers in Canada, Australia, and New Zealand. It’s about time someone shook up the logistics playbook. The Nuts and Bolts of the New Shipping System Imagine being...

Lick the Plate Hits 2,000 Shows with Clown Band

They say good things come in bizarre packages, and that's exactly the case as David Boylan's Lick the Plate zany celebration marks 15 years on air with its 2,000th episode. If you think of radio as a predictable endeavor, well, you're not tuned into Lick the Plate. A Milepost Draped in Multicolored Fabrics When you're browsing through colorful avenues of radio fame, it's...

2026 Buy-Side Index Reveals State Market Variance

Toss out your one-size-fits-all real estate predictions; the Q2 2026 Buy-Side Index just unveiled some real whoppers about the housing market. What we're seeing isn't your typical year-over-year growth across the board. Nope, we're seeing splits as sharp as a knife between states. Some places are shooting up in price, while others seem to be stuck in mud. Price Surges and...

Fermi's Founder Pushes for Board Overhaul: What's Next?

Fermi's Roller Coaster: A Founder’s Stand Seems like Fermi Inc. is on a wild ride through the business landscape, and it's giving shareholders more whiplash than satisfaction these days. Toby Neugebauer, co-founder of Fermi and the loudest voice in the room, is feeling like his company is facing some serious turbulence and seems determined not to sit idly by as it hits...